Janux Therapeutics (JANX) Change in Acquisitions & Divestments (2021 - 2026)

Janux Therapeutics (JANX) has reported Change in Acquisitions & Divestments for 6 consecutive years, with $121.3 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Change in Acquisitions & Divestments rose 287.94% year-over-year to $121.3 million; the TTM figure through Mar 2026 stood at $495.3 million (up 176.43% YoY), while the FY2025 annual figure was $405.3 million, up 90.35% from the prior year.
• Change in Acquisitions & Divestments slipped to $121.3 million in Q1 2026 per JANX's latest filing, from $152.9 million in the prior quarter.
• Across five years, Change in Acquisitions & Divestments topped out at $152.9 million in Q4 2025 and bottomed at $31.3 million in Q1 2025.
• Historically, Change in Acquisitions & Divestments has averaged $81.0 million across 5 years, with a median of $77.1 million in 2022.
• Annual changes were most pronounced in 2022 — Change in Acquisitions & Divestments soared 427.21% — and 2024, when it slumped 52.89%.
• Janux Therapeutics' Change in Acquisitions & Divestments stood at $86.5 million in 2022, then slumped by 48.27% to $44.8 million in 2023, then grew by 29.61% to $58.0 million in 2024, then jumped by 163.67% to $152.9 million in 2025, then retreated by 20.67% to $121.3 million in 2026.
• Business Quant data shows JANX's Change in Acquisitions & Divestments at $121.3 million in Q1 2026, $152.9 million in Q4 2025, and $126.4 million in Q3 2025.